|
Standard Review for Gilead’s Oncology Candidate
Yahoo News The patients were refractory to both Roche’s (OTC:RHHBY) Rituxan (rituximab) and to chemotherapy inclusive alkylating-agent. A decision from the FDA is expected by Sep 11, 2014. Apart from iNHL, idelalisib is also being evaluated in other oncology … |
|
3 Reasons to Buy Gilead Sciences, Inc.
Motley Fool Last December, Gilead announced that a late-stage trial for idelalisib was stopped early because patients receiving a combo of idelalisib plus rituximab showed a highly significant improvement in overall survival and progression-free survival. With the … Standard Review for Gilead’s Oncology Candidate – Analyst BlogNASDAQ Gilead’s Idelalisib NDA accepted by US FDA for the treatment of refractory …MENAFN.COM |
|
Standard Review for Gileads Oncology Candidate
Zacks.com The patients were refractory to both Roche’s (RHHBY) Rituxan (rituximab) and to chemotherapy inclusive alkylating-agent. A decision from the FDA is expected by Sep 11, 2014. Apart from iNHL, idelalisib is also being evaluated in other oncology … Gilead’s Idelalisib NDA accepted by US FDA for the treatment of refractory …MENAFN.COM |
More teens lack HSV-1 antibodiesModernMedicineAn increasing number of American adolescents lack herpes simplex virus (HSV) type 1 antibodies, making them more susceptible to genital herpes following sexual debut, according to a recent study in The Jour…
|
Agenus Inc. – “Are We Getting Closer to Curing Cancer With Checkpoint …
MarketWatch Read the full blog post on TheChairmansBlog.com ( http://www.thechairmansblog.com/agenus/garo-armen/getting-closer-curing-cancer-checkpoint-antibodies/ ). About Agenus. Agenus Inc. is a biotechnology company working to develop treatments for … |
Drug Discovery & Development |
Cell Therapeutics reaquire rights to two anti-cancer compounds from Novartis
pharmabiz.com CTI is currently accruing patients into a phase III trial comparing Pixuvri and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. Pixuvri does not have marketing approval in the United States. Opaxio (paclitaxel … Cell Therapeutics Reveals Drug Portfolio Progress, Outlook For 2014 – UpdateNASDAQ Cell Therapeutics Inc : Cell Therapeutics Announces 2014 Outlook and Recent …4-traders (press release) |
Drug Discovery & Development |
Cell Therapeutics Reveals Drug Portfolio Progress, Outlook For 2014 – Update
NASDAQ … change the primary endpoint of the Phase 3 PIX-R, or PIX306, post-marketing commitment study of pixantrone-rituximab versus gemcitabine-rituximab for patients with relapsed B-cell non-Hodgkin lymphoma from overall survival to progression-free survival. Cell Therapeutics reaquire rights to two anti-cancer compounds from Novartispharmabiz.com Cell Therapeutics Inc.: Cell Therapeutics Announces 2014 Outlook and Recent …The Wall Street Transcript |
|
Portola Pharmaceuticals Inc (PTLA): Portola Pharmaceuticals’ CEO Presents at …
Seeking Alpha Targeting not only B cell signaling but cytokine signaling via JAK we think is potential beneficial for patients that are not addressed by the other agents including Ibrutinib PI3 kinase inhibitors, rituximab. We have an ongoing, as I said, Phase I/II … |
Drug Discovery & Development |
FDA Accepts NDA for Gilead Lymphoma Drug
Drug Discovery & Development 11, 2013, was supported by a single arm Phase 2 study (Study 101-09) evaluating idelalisib in patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. Following Gilead’s NDA submission for … US FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment …Investor’s Business Daily |
Cell Therapeutics to reacquire rights to two anti-cancer compoundsThe Pharma LetterCell Thera is currently accruing patients into a Phase III trial comparing Pixuvri and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. …